Purpose: Infection in neutropenic patients is potentially life-threatening and carries important implications for hospital resource use. Prophylactic administration of cytokines may reduce the severity of neutropenia, but involves the treatment of all patients for the possible benefit of a minority. This study evaluates whether treatment with cytokines in the setting of established febrile neutropenia will influence outcome and be potentially more cost-effective.
Purpose: Infection in neutropenic patients is potentially life-threatening and carries important implications for hospital resource use. Prophylactic administration of cytokines may reduce the severity of neutropenia, but involves the treatment of all patients for the possible benefit of a minority. This study evaluates whether treatment with cytokines in the setting of established febrile neutropenia will influence outcome and be potentially more cost-effective.
Patients and Methods: In a double-blind study, pediatric patients with fever and severe neutropenia were randomized to receive granulocyte colony-stimulating factor ([G-CSF] filgrastim; 5 /ig/kg/d) or placebo, in addition to antibiotics. The study protocol required a resolution of fever and a neutrophil count > 0.2 x 10 9 /L for hospital discharge. Patients could be randomized for up INFECTION ASSOCIATED with neutropenia remains a major cause of morbidity and mortality for many chemotherapy regimens. Myelosuppression and the risk of sepsis is frequently the principal dose-limiting toxicity of chemotherapy. Effective therapy for many pediatric malignancies involves the use of intensive cytotoxic regimens that produce prolonged and profound neutropenia in patients with both leukemias and solid malignancies. Although the prompt initiation of empiric broad-spectrum antibiotics has dramatically reduced the mortality due to febrile neutropenia' 2 and mortality is now rare for pediatric patients, 3 hospital stay is frequently prolonged and scheduled cycles of chemotherapy may be delayed.
The resolution of granulocytopenia has been identified as an important factor in the recovery from febrile neutropenia. 4 Hematopoietic colony-stimulating factors (CSFs) that act on the myeloid lineage, such as granulocyte CSF (G-CSF) and granulocyte-macrophage CSF (GM-CSF), will produce dose-dependent increases in peripheralblood neutrophil counts following myelosuppressive chemotherapy. 5 In addition, G-CSF stimulates the antimicrobial function of mature granulocytes. 6 However, it remains unclear whether CSFs have a role in accelerating the recovery of patients when commenced after the onset of febrile neutropenia. 7 This study was designed to determine if the addition of G-CSF, when commenced with antibiotics in the setting of established febrile neutropenia, would reduce the duration of hospital stay, the intensity of supportive care required such as parenteral nutrition and antifungal treatment, and the cost to manage fever with neutropenia in pediatric patients.
PATIENTS AND METHODS

Patients and Treatment
The study recruited patients admitted to the pediatric oncology units of the Royal Marsden NHS Trust (RMH) and The Birmingham Children's Hospital (BCH) over a 14-month period. Neither hospital had a policy of administering prophylactic CSF or prophylactic antibiotic therapy following chemotherapy. Eligible patients were 17 years, with an oral temperature documented at 2 38.5°C on one occasion or 38'C on two occasions, or with clinical evidence of sepsis such as rigors or septic shock. Axillary temperatures 0.5°C lower were accepted. An absolute neutrophil count, including immature forms, of less than 0.5 X 10 MITCHELL ET AL support were excluded, as were patients under treatment with prophylactic CSFs or those with a history of adverse reactions to G-CSF. Most study patients had indwelling Hickman lines.
The study drug was filgrastim (recombinant human methionyl G-CSF) supplied by Amgen Roche (Cambridge, United Kingdom). Patients were randomized to receive filgrastim 5 g/kg/d intravenously (IV) over 30 minutes or placebo, to commence within 24 hours of antibiotic therapy. G-CSF/placebo was continued until withdrawal of IV antibiotic therapy, but was discontinued if the neutrophil count reached 1 X 109/L. Individual patients were eligible for randomization on up to four occasions, provided the previous episode of febrile neutropenia had resolved and a further cycle of chemotherapy had been given, ie, the episodes were independent. The study drug and placebo were delivered to the ward in identically labeled syringes, and the ward staff and investigators were unaware of treatment allocation until the study had been completed.
Following admission, cultures of blood and clinically indicated sites were taken and empiric broad-spectrum antibiotic therapy was commenced according to local policies (RMH, gentamicin/piperacillin/flucloxacillin; BCH, imipenem-cilastatin/gentamicin). When the blood culture was negative for pathogens, 72 hours afebrile and a neutrophil count 0.2 x 10 9 /L were adequate for discharge, provided the child's general condition was satisfactory. When blood culture was positive, 7 days' antibiotic therapy was to be given. If patients remained febrile after 48 hours, antibiotics were changed to second-line combinations (RMH, gentamicin/ciprofloxacin; BCH, vancomycin/ciprofloxacin), and antifungal therapy was initiated, if clinically appropriate, in patients who remained febrile on the fifth day of hospitalization.
Study Design and Statistical Methodology
In designing the study, it was estimated that 166 randomizations would be required to identify a 20% reduction in hospital stay, the primary end point of the study, with a power of 90% at a significance level of .05 (two-tailed test).
The primary end point of the study was duration of hospital stay, which was defined as beginning at randomization and ending when the patient was discharged following completion of treatment for febrile neutropenia. Other end points were chosen that influenced both the cost of care and the patient quality of life; namely duration of IV antibiotic usage, time to resolution of fever (defined as < 37.5C), and time for recovery of the neutrophil count to 0.2 and 0.5 x 10 9 /L (including immature forms). Other data prospectively recorded for analysis were the change to second-line antibiotics, use of antifungal agents, blood products, and total parenteral nutrition (TPN), and toxicity of the trial drug. The study design incorporated a cost analysis, and data were prospectively collected for use of hospital bed days, antimicrobial agents, blood products, TPN, and G-CSF. Hospital bed cost was an average figure that included general costs to run the ward, staffing, and basic ward pharmaceuticals, as well as laboratory tests and imaging investigations. The wholesale cost of antimicrobial agents, filgrastim, TPN, and blood products was used, and the cost of tubing and IV sets was included. Stratification of patients by hospital of treatment and first or subsequent randomization was undertaken prospectively. Analysis of other subgroups was performed retrospectively with a view to provide guidance for future studies.
All randomized patient episodes included in the study were analyzed on an intention-to-treat basis. Withdrawals from the study were balanced between the two groups, and hospitalization for these patients was deemed to have terminated at study withdrawal.
Statistical analysis was based on nonparametric methods, given the skewed nature of the data. Transformations were attempted, but did not normalize the data sufficiently to warrant using parametric methods. The results are therefore presented as number (percent) or median (IQR), with comparisons based on Mann-Whitney or X 2 tests as appropriate. Where appropriate, survival analysis techniques were also used as an alternative approach and confirmed the results found with the Mann-Whitney comparison (not presented).
Centralized pharmacy dispensing allowed the use of G-CSF vials for multiple use, and the cost per milligram used was calculated rather than whole vials per dose.
RESULTS
One hundred eighteen patients were randomized at least once; six were removed because they did not fulfill the eligibility criteria. The remaining 112 patients were studied at 186 febrile episodes (112 first and 74 subsequent). These were included in the intent-to-treat analysis, 94 randomized to receive G-CSF and 92 placebo. Five patient episodes included in the analysis were withdrawn from the study (three G-CSF and two placebo) because of transfer to another hospital (three episodes) or withdrawal at the parents' request (two episodes). There were no deaths on either arm of the study. Patient characteristics are listed in Table 1 . There were no statistically significant differences between either the randomization groups or the patients at first or subsequent randomization.
Hospital Stay and Febrile Neutropenia
Results for the clinical and laboratory study end points are listed in Table 2 . For all patients, febrile neutropenia was successfully treated, with no readmissions for recurrent sepsis and no deaths. The median duration of hospital stay was significantly reduced from 7 days for patients randomized to placebo to 5 days for the G-CSF arm (P = .04). Figure I shows the proportion of patients who remained in hospital by study day.
Although the study was not designed for specific detection of differences in the time to fever resolution, this appeared shorter in those who received G-CSF (median, 2 v 3 days), but the difference was not significant (Table  2 ). Fever recurred after 2 afebrile days in 13 of 94 G-CSF patients (14%) and 12 of 92 placebo patients (13%). Recovery of the neutrophil count to 0.5 X 10 9 /L occurred at a median of 3 days for G-CSF patients, significantly faster than the 5 days required for placebo patients (P = .02). Recovery to a count of 0.2 x 10 9 /L was also shorter, but this was not significantly different (Fig 2) . The lack of a further increase in the percentage with a Fifty-six G-CSF, 56 placebo. tTwenty-six first randomization to G-CSF, 23 first randomization to placebo.
G-CSF IN FEBRILE NEUTROPENIA FOR CHILDREN
tHickman-line or exit-site infection, soft tissue infection, consolidation on chest x-ray. neutrophil count more than 0.5 x 10 9 /L between days 4 and 5 was due to a small number of patients being discharged on day 5 due to count recovery and early resolution of fever. This analysis did not include 52 patients (28%) who had already been treated and discharged before the neutrophil count reached 0.5 x 10 9 /L. Further analysis using survival techniques until time of neutrophil recovery to 0.5 X 109/L as the event time and otherwise censoring patients on day of discharge (ie, all patients) confirmed this faster recovery in G-CSF patients (logrank test, P = .006). Overall, G-CSF patients were discharged from hospital with a median neutrophil count of 1.65 x 10 9 /L, as compared with 0.73 x 10 9 /L for placebo patients (P = .003; Table 2 ).
No symptomatic toxicity was reported for patients randomized to receive G-CSF. There was no evidence of G-CSF-related hepatic or hematologic toxicity, and transfusion requirements of patients in the two randomized groups were similar.
Supportive Care
A median of 5 days' antibiotic therapy was required by G-CSF patients and 6 days by the placebo group (P = .02; Table 2 ). However, there was no difference in the proportion of patients who required a change to second-line antibiotic or amphotericin therapy. The proportion of patients who required TPN or transfusion of blood products was similar for the two groups. Resolution of mucositis was not a primary end point in the study, but there was some indication that this resolved more quickly in G-CSF patients (median, 3 v 4.5 days). This was not statistically significant. 
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Elective G-CSF Therapy
The clinical condition of 15 patients (four G-CSF and 11 placebo) was judged by physicians to be sufficiently poor to warrant discontinuation of the study medication and elective commencement of G-CSF after a median of 5 days on study. The dose of filgrastim given electively, 5 g/kg/d, was the same as for the study drug. The randomization code was not broken in these patients while the study continued. Patients who electively commenced G-CSF were in poor clinical condition, with a median play performance status 8 of 50 (child lies around much of the day, with no active play), as compared with 80 (child is active, but tires more quickly) for the rest of the study cohort (P -.001). Patients who electively changed had a hospital stay of > 10 days, as compared with a median 6-day stay for the whole group. Considering patients in hospital for 10 days, fewer on the G-CSF study arm were electively put on G-CSF: four of 18 (22%), compared with 11 of 24 (46%) on the placebo arm (P = .05).
Further Analysis
Further investigative analysis was performed using duration of hospital stay as the end point within specific groups of patients who were considered more (or less) likely to benefit from G-CSF.
G-CSF appeared to benefit three subgroups in particular: those with acute lymphoblastic leukemia (ALL) or receiving not-dose-intensive alkylating agent-based regimens; those with early onset (< 10 days) of fever after chemotherapy; and those without documented septicemia or focal infection.
Patients with ALL who received G-CSF had a significant shortening of hospital stay (P -.01) from a median of 7 to 5 days (Fig 3) .
No benefit was observed in patients who received intensive, predominantly alkylating agent-based regimens (P = .8), whereas with other treatments the median hospital stay was reduced (P .005). Patients with early onset (< 10 days) of febrile neutropenia (P = .01; > 10 days, P = .9) and patients without a documented infection site (P = .02; site present, P = .9) also benefitted.
The influence of repeat randomization was addressed. One hundred twelve patients were analyzed after the first randomization alone and 49 on 74 occasions after the second or subsequent randomizations. The median duration of hospital stay for G-CSF versus placebo was 5.5 versus 7.0 days and 5.0 versus 6.5 days, respectively (P = .19 and .10). Although not significant, the trend remains clear. A lack of influence of previous G-CSF or placebo treatment was supported by the same proportions of patients being readmitted (and rerandomized) after either treatment. This implies that patients were no more likely to return after receiving one or the other intervention after a previous course of chemotherapy.
Cost Analysis
The duration of hospital stay was the main determinant of the cost to treat febrile neutropenia ( Table 3 ). The 2-day reduction in hospital stay for G-CSF patients reduced the cost 29%, from a median of $5,046 (placebo) to $3,604 (G-CSF) per patient admission (P = .04). The median cost of antimicrobial agents was reduced by 27% in patients on G-CSF (P = .04). There was a 20% reduction in overall cost, from a median of $5,169 (placebo) to $4,147 (G-CSF) per patient admission (P = .11). Cost savings were greater for patients with ALL randomized to receive G-CSF, with a 28% reduction in median overall costs (including G-CSF costs) from $5,460 (placebo) to $3,946 (G-CSF) per patient admission, and this difference was significant (P < .04).
DISCUSSION
This study demonstrates that the use of filgrastim produced modest but significant improvements in important clinical end points in the treatment of children with febrile neutropenia. The median hospital stay was reduced by 2 days and the duration of antibiotic therapy by 1 day. The reduction of hospital stay and medical interventions are important considerations in the treatment of children with malignancy in terms of both cost and quality of life. Patients who received G-CSF had more rapid neutrophil recovery, and at discharge from hospital they had higher neutrophil levels. The overall median cost to treat an episode of febrile neutropenia was reduced by 20% for G-CSF patients. This reduction in cost was principally due to a shortening of hospital stay, and the additional cost of G-CSF was minor by comparison. It should be mentioned that although a reduced hospital stay will reduce the cost for an individual case, since the bed is usually filled immediately by another patient, overall unit costs may not be influenced. Depending on the nature of cost reimbursement, increased patient turnover may or may not be cost-saving.
The length of hospital stay was to an extent dependent on hospital policies for the treatment of febrile neutropenia, such as a minimum of 7 days' antibiotic therapy if blood cultures were positive. This could explain the lack of benefit of G-CSF with proven infection. Other Days in hospital reasons to delay discharge after early neutrophil count recovery include soft tissue infection, abnormal chest xray, or prolonged mucositis. Of particular importance in evaluation of the effect of CSFs in febrile neutropenia is any policy for the neutrophil threshold required for hospital discharge. If this threshold is high, any reduction in the duration of neutropenia will have a marked effect on hospital stay. Whereas the practice for adult patients is to require -0.5 to 1.0 x 10 9 /L neutrophils before discharge, 2 9 pediatric practice is less stringent, 0 and the study design followed our policy to require a neutrophil count of only 0.2 x 109/L for discharge. Patients were not discharged until a median of 2 to 3 days after reaching this neutrophil count. With such a low threshold, the 
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decision to discharge was mainly dependent on the general condition of the child and the requirement for 72 hours without fever. A benefit for CSF use in children with established febrile neutropenia was also found by Riikonen et al" in a small randomized study of 58 episodes. GM-CSF reduced the median hospital stay by 1 day, from 10 days to 9 days, but also markedly reduced the proportion of children who required a prolonged hospital stay. The data regarding CSFs for established febrile neutropenia in adult cancer patients are also limited.
29 ' 2' 3 Differences in study guidelines with regard to entry criteria or indications for discontinuation of antibiotics in relation to neutrophil count recovery are likely to influence any impact of G-CSF. More conservative policies will probably diminish the significance of earlier neutrophil count recovery (Table 4) . Mayordomo et a1 9 showed a 2-day reduction in hospitalization with either G-CSF or GM-CSF in a study of 121 adult patients. G-CSF (filgrastim) did not significantly reduce the median hospital stay in an Australian study of 218 adult patients. 2 In both of these adult studies, CSFs reduced the duration of neutropenia and had a particular effect to reduce the need for prolonged hospitalization. In the current study, we did not find a similar reduction in prolonged hospitalization in the G-CSF arm. It is likely that the increased use of elective G- CSF in clinically unwell placebo patients reduced any difference in hospital stay between the study arms. It is noteworthy that placebo patients were more often identified by clinicians as being sufficiently unwell to be electively commenced on G-CSF. The current study was not designed to recruit sufficient numbers of patients for definitive identification of subgroups likely to gain most from G-CSF therapy. However, a retrospective analysis of subgroups was undertaken to give guidance in the design of further studies. Patients who benefitted most from G-CSF therapy were those with ALL who had not received alkylating agents such as cyclophosphamide or ifosfamide, whereas those who received dose-intensive, alkylating agent-based regimens for solid tumors failed to benefit. Patients who developed febrile neutropenia shortly after chemotherapy, a factor associated with prolonged hospitalization, showed a benefit. However, in general, the subgroups of both pediatric and adult patients likely to benefit most from the use of CSFs in established febrile neutropenia remain to be defined.
The prophylactic use of CSFs, commencing immediately after chemotherapy and extending through the period of neutropenia, has been well studied. This approach has been shown to be effective in adults,'4 -' 7 with an approximate 50% reduction in febrile neutropenia, and it has been recommended that routine prophylactic CSF is appropriate when the risk of febrile neutropenia is greater than 40%. 7 However, for pediatric patients, the situation with regard to prophylactic CSFs remains far from clear and the results have been disappointing. G-CSF reduced neutropenia and the incidence of febrile neutropenia in one study,' 8 but had little effect in another.' 9 Although GM-CSF did reduce neutropenia in most 20' 24 but not all 25 studies, the incidence of febrile neutropenia was reduced only in some. 23 2 4 Furthermore, prophylactic CSFs must be given by daily subcutaneous injection, which presents obvious problems in the pediatric age group, especially if only a minority of patients subsequently benefit. Obviously, prophylactic and interventional use of CSFs are not mutually exclusive, and continuing G-CSF after admission would be appropriate in some patients.
This study has shown that the use of G-CSF in children with established febrile neutropenia influences important clinical end points and indicated the potential for a reduced overall treatment cost. It seems likely that some subgroups of patients such as those who receive less profoundly myelosuppressive regimens might benefit more from this approach. However, these results remain applicable to the general pediatric oncology practice population and provide evidence that the use of G-CSF, in addition to antibiotics, reduces the morbidity of established febrile neutropenia.
